A. Van Vreckem

746 total citations
16 papers, 597 citations indexed

About

A. Van Vreckem is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, A. Van Vreckem has authored 16 papers receiving a total of 597 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 5 papers in Cancer Research and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in A. Van Vreckem's work include Cancer Treatment and Pharmacology (9 papers), Breast Cancer Treatment Studies (5 papers) and Estrogen and related hormone effects (4 papers). A. Van Vreckem is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), Breast Cancer Treatment Studies (5 papers) and Estrogen and related hormone effects (4 papers). A. Van Vreckem collaborates with scholars based in Belgium, Netherlands and United Kingdom. A. Van Vreckem's co-authors include Martine Piccart, Robert Paridaens, Richard Sylvester, Ahmad Awada, Robert E. Coleman, P.F. Bruning, Stephen Houston, Teresa Gamucci, J.G.M. Klijn and Laura Biganzoli and has published in prestigious journals such as Journal of Clinical Oncology, Statistics in Medicine and European Journal of Cancer.

In The Last Decade

A. Van Vreckem

14 papers receiving 569 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Van Vreckem Belgium 7 459 216 98 76 72 16 597
U. Klaassen Germany 14 642 1.4× 203 0.9× 130 1.3× 99 1.3× 115 1.6× 31 777
Nicholas Wilcken Australia 14 463 1.0× 307 1.4× 155 1.6× 27 0.4× 89 1.2× 27 658
Gustavo Fonseca United States 7 371 0.8× 156 0.7× 47 0.5× 78 1.0× 76 1.1× 19 513
Kathleen A. Havlin United States 11 588 1.3× 101 0.5× 121 1.2× 37 0.5× 154 2.1× 27 744
J Sjöström Sweden 12 600 1.3× 281 1.3× 115 1.2× 56 0.7× 216 3.0× 15 821
A. Vindevoghel Belgium 10 647 1.4× 474 2.2× 88 0.9× 56 0.7× 134 1.9× 23 868
P.-E. Jönsson Sweden 11 340 0.7× 280 1.3× 106 1.1× 27 0.4× 111 1.5× 23 623
Jyotirmoy Dey United States 11 151 0.3× 249 1.2× 76 0.8× 98 1.3× 117 1.6× 20 573
Stuart J. Tipping United States 6 297 0.6× 49 0.2× 80 0.8× 46 0.6× 141 2.0× 9 584
Antonio Marrazzo Italy 14 282 0.6× 231 1.1× 116 1.2× 34 0.4× 151 2.1× 39 724

Countries citing papers authored by A. Van Vreckem

Since Specialization
Citations

This map shows the geographic impact of A. Van Vreckem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Van Vreckem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Van Vreckem more than expected).

Fields of papers citing papers by A. Van Vreckem

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Van Vreckem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Van Vreckem. The network helps show where A. Van Vreckem may publish in the future.

Co-authorship network of co-authors of A. Van Vreckem

This figure shows the co-authorship network connecting the top 25 collaborators of A. Van Vreckem. A scholar is included among the top collaborators of A. Van Vreckem based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Van Vreckem. A. Van Vreckem is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Steen, Kristel Van, Desmond Curran, Geert Molenberghs, et al.. (2002). Multicollinearity in prognostic factor analyses using the EORTC QLQ‐C30: identification and impact on model selection. Statistics in Medicine. 21(24). 3865–3884. 82 indexed citations
2.
3.
Hamilton, A., Denis Larsimont, Robert Paridaens, et al.. (2000). A Study of the Value of p53, HER2, and Bcl-2 in the Prediction of Response to Doxorubicin and Paclitaxel as Single Agents in Metastatic Breast Cancer: A Companion Study to EORTC 10923. Clinical Breast Cancer. 1(3). 233–240. 42 indexed citations
4.
Paridaens, Robert, Laura Biganzoli, P.F. Bruning, et al.. (2000). Paclitaxel Versus Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: A European Organization for Research and Treatment of Cancer Randomized Study With Cross-Over. Journal of Clinical Oncology. 18(4). 724–724. 288 indexed citations
5.
Hamilton, Anne, J.A. Roy, L.V.A.M. Beex, et al.. (2000). EORTC 10941: A phase II study of liarozole in postmenopausal patients with ‘Chemotherapy-Resistant’ or ‘Potentially Hormone Sensitive’ metastatic breast cancer. Breast Cancer Research and Treatment. 60(2). 181–188. 3 indexed citations
6.
Paridaens, R., M. Nooij, Jan G.M. Klijn, et al.. (1998). Vorozole (Rivizor???): an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure. Anti-Cancer Drugs. 9(1). 29–35. 4 indexed citations
7.
Valeriola, Dominique de, Ahmad Awada, A. Van Vreckem, et al.. (1998). Influence of amifostine (A) on the toxicity and pharmacokinetics (PK) of docetaxel (D) in breast cancer patients: An EORTC-IDBBC study. European Journal of Cancer. 34. S19–S19. 2 indexed citations
8.
Paridaens, Robert, P.F. Bruning, Teresa Gamucci, et al.. (1997). Taxol (T) versus doxorubicin (D) as first-line chemotherapy (CT) in advanced breast cancer (ABC): An EORTC randomized study with crossover. European Journal of Cancer. 33. S145–S145. 3 indexed citations
9.
10.
Awada, Ahmad, A. Van Vreckem, Robert Paridaens, et al.. (1997). EORTC-IDBBC (Investigational Drug Branch For Breast Cancer): 5 Years of European collaboration in new drug development for breast cancer. European Journal of Cancer. 33(8). 1173–1176. 2 indexed citations
11.
Kerger, Joseph, Ahmad Awada, F. Geurs, et al.. (1997). Mitomycin C and Vinblastine in combination with Amifostine in metastatic breast cancer. Supportive Care in Cancer. 5(5). 414–416. 6 indexed citations
12.
13.
Piccart, Martine, P.F. Bruning, Teresa Gamucci, et al.. (1996). An ongoing European organization for research and treatment of cancer crossover trial comparing single-agent paclitaxel and doxorubicin as first- and second-line treatment of advanced breast cancer.. PubMed. 23(5 Suppl 11). 11–5. 12 indexed citations
14.
15.
Paridaens, Robert, Martine Piccart, J.G.M. Klijn, et al.. (1993). Phase II study of the eortc breast group with vorozole (R 83842), a new non-steroidal aromatase inhibitor in metastatic breast cancer (MBC) — preliminary results. European Journal of Cancer. 29. S86–S86.
16.
Valeriola, Dominique de, Sandrine Gaillard, Eva Tomiak, et al.. (1993). Study of excretion balance, metabolism and protein binding of Caradiolabelled Taxotere (TXT) (RP56976, NSC628503) in cancer patients.. Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles). 373. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by U. Klaassen Breakdown of academic impact, for papers by Nicholas Wilcken Breakdown of academic impact, for papers by Gustavo Fonseca Breakdown of academic impact, for papers by Kathleen A. Havlin Breakdown of academic impact, for papers by J Sjöström Breakdown of academic impact, for papers by A. Vindevoghel Breakdown of academic impact, for papers by P.-E. Jönsson Breakdown of academic impact, for papers by Jyotirmoy Dey Breakdown of academic impact, for papers by Stuart J. Tipping Breakdown of academic impact, for papers by Antonio Marrazzo
Rankless by CCL
2026